Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Total Liabilities
Everything the company owes to creditors and other parties.
Alumis Inc. Common StockNASDAQ: ALMS
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities falls 13.6% from a year ago
Total liabilities stood at $108.46M at the end of Q2 FY2026, down 13.6% from a year earlier and up 3.7% from the prior quarter. Over 3 fiscal years it compounded at -28.6% a year.
Context
- Total liabilities amounted to 19.3% of total assets at the end of Q2 FY2026, down 1.2 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -13.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 110.64M USD
- Year-over-year change
- +36.8%
- 3-year CAGR
- -28.6%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 110.64M | +36.8% |
| FY2024 | 2024-12-31 | 80.89M | -81.1% |
| FY2023 | 2023-12-31 | 428.87M | +41.4% |
| FY2022 | 2022-12-31 | 303.41M | — |
Total Liabilities vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -13.6% is the 4th highest of 9, against a peer median of -18.1%.
- Total liabilities amounts to 19.3% of total assets for ALMS, versus a peer median of 27.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $316.94M USD | -18.3% | -2.1% | 96.1% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $108.46M USD | -13.6% | -28.6% | 19.3% |
| Mar 2026 | $104.71M USD | -33.5% | -6.2% | 20.8% | |
| Mar 2026 | $55.07M USD | +1.9% | +0.2% | 27.7% | |
| Mar 2026 | $31.57M USD | +98.4% | -9.0% | 31.6% | |
| Mar 2026 | $24.33M USD | -17.8% | -2.8% | 36.6% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €18.7M EUR | — | — | 11.3% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $18.11M USD | -19.4% | -57.5% | 17.1% |
| Mar 2026 | €12.01M EUR | -27.4% | -0.9% | 24.5% | |
| Dec 2025 | $11.44M USD | +55.7% | +18.3% | 99.5% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | -18.1% | -2.4% | 27.7% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.